Compare Amphastar Pharmaceuticals Inc (AMPH) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Snowflake Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Snowflake Inc trades at $270.82 (market cap $90.62B). The key difference: Snowflake Inc is far larger — about 109.7× Amphastar Pharmaceuticals Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SNOW | |
|---|---|---|
Market Cap | $826.08M | $90.62B |
Sector | Health | Technology |
52-Week High | $30.81 | $280.16 |
52-Week Low | $16.87 | $121.11 |
Enterprise Value | $1.22B | $90.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Snowflake (SNOW) trades at $261.45, down 2.26% today but maintains strong technical momentum with bullish moving averages and a consensus price target of $294.31. The company shows impressive revenue growth from $1.2B in 2022 to $3.63B in 2025, though it remains unprofitable with a -23.79% net margin. Recent earnings beats and accelerating AI Data Cloud adoption signal strong business momentum despite premium valuation metrics.
Snowflake presents a growth-focused investment opportunity with 80.77% analyst buy ratings and projected revenue reaching $5B in 2026. Key risks include persistent losses, intense cloud competition, and premium valuation at 17.7x P/S ratio. The stock's upside depends on continued AI platform adoption and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
